Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  mercaptopurine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 47 for your search:
Start Over
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
LAL-BR/2001: Study Treatment to Low Risk ALL
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 and under
Sponsor: Other
Protocol IDs: LAL-BR/2001, NCT00526175
The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and under
Sponsor: Other
Protocol IDs: 2007016, NCT00846703
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: LAL-AR/2003, NCT00853008
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: LAL Ph-2008, NCT01491763
Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under at diagnosis
Sponsor: Other
Protocol IDs: 6-MP formulation, 2013-001236-21, NCT01906671
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 30
Sponsor: Other
Protocol IDs: LAL-RI/2008, NCT02036489
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: CDR0000686545, 2009-012758-18, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Phase: Phase III
Type: Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: JALSG ALL202-O, NCT00131027
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, R37CA036401, 5R01CA090246, Aspar PK-PD-T16, NCI-2011-01254, NCT00549848
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: CDR0000613220, MOTOL-ALL-IC-BFM-2002, EU-20871, ALL-IC-BFM-2002, NCT00764907
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: NOPHO ALL2008 consolidation, NCT00816049
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: AIEOP-BFM ALL 2009, NCT01117441
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to < 10
Sponsor: NCI, Other
Protocol IDs: AALL0932, NCI-2011-02599, CDR0000683227, U10CA098543, COG-AALL0932, NCT01190930
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: AALL1131, NCI-2011-03797, CDR0000706370, U10CA098543, COG-AALL1131, NCT01406756
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training
Status: Active
Age: 12 to 20
Sponsor: NCI, Other
Protocol IDs: ACCL1033, NCI-2012-00105, CDR0000721559, COG-ACCL1033, U10CA095861, NCT01503632
Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: POWH-CRE-2008.077-T, CDR0000595184, NCT00707083
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 35 to 70
Sponsor: NCI
Protocol IDs: NCI-2013-02229, ECOG-E1910, E1910, U10CA180820, U10CA021115, NCT02003222
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 30
Sponsor: NCI
Protocol IDs: NCI-2014-00712, AALL1231, U10CA180886, U10CA098543, NCT02112916
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: Under 16
Sponsor: Other
Protocol IDs: 2010001, NCT02200978
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2010-0991, NCI-2011-01123, NCT01371630
Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 2 to 18
Sponsor: Other
Protocol IDs: JMC-2014-6TG/6MP, NCT02141100
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 24
Sponsor: Other
Protocol IDs: JALSG ALL202-U, NCT00131053
"Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: LAL1104, NCT00475280
Start Over